With new data, UBI Asia hoping for review of vaccine EUA application
09/06/2021 11:00 PM
Taiwan-based United Biomedical Inc. (UBI) Asia is planning to reapply for emergency use authorization (EUA) for its COVID-19 vaccine based on what it described as very strong data after giving clinical trial subjects a third dose of the vaccine.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
U.S. dollar closes higher on Taipei forex market
11/27/2024 05:13 PM - Business
Consumer confidence down as credit controls cool property market
11/27/2024 05:05 PM - Politics
No need to fear 'State Organs' bomb threats: Police
11/27/2024 05:02 PM - Business
Taiwan should ease rules on foreign students working: Hotel executive
11/27/2024 04:23 PM - Society
MOL official at center of suicide controversy banned from leaving Taiwan
11/27/2024 04:04 PM